BACKGROUND: Cerebrovascular thrombosis is a major source of morbidity and mortality after surgery, but thromboprophylaxis in this setting is limited because of the formidable risk of perioperative bleeding. Thrombolytics (eg, tissue-type plasminogen activator [tPA]) cannot be used prophylactically in this high-risk setting because of their short duration of action and risk of causing hemorrhage and central nervous system damage. We found that coupling tPA to carrier red blood cells (RBCs) prolongs and localizes tPA activity within the bloodstream and converts it into a thromboprophylactic agent, RBC/tPA. To evaluate the utility of this new approach for preventing cerebrovascular thrombosis, we examined the effect of RBC/tPA in animal models of cerebrovascular thromboembolism and ischemia. METHODS AND RESULTS: Preformed fibrin microemboli were injected into the middle carotid artery of mice, occluding downstream perfusion and causing severe infarction and 50% mortality within 48 hours. Preinjected RBC/tPA rapidly lysed nascent cerebral thromboemboli, providing rapid, durable reperfusion and reducing morbidity and mortality. These beneficial effects were not achieved by preinjection of tPA, even at a 10-fold higher dose, which increased mortality from 50% to 90% by 10 hours after embolization. RBC/tPA injected 10 minutes after tail amputation to simulate postsurgical hemostasis did not cause bleeding from the wound, whereas soluble tPA caused profuse bleeding. RBC/tPA neither aggravated brain damage caused by focal ischemia in a filament model of middle carotid artery occlusion nor caused postthrombotic hemorrhage in hypertensive rats. CONCLUSIONS: These results suggest a potential RBC/tPA utility as thromboprophylaxis in patients who are at risk for acute cerebrovascular thromboembolism.
BACKGROUND:Cerebrovascular thrombosis is a major source of morbidity and mortality after surgery, but thromboprophylaxis in this setting is limited because of the formidable risk of perioperative bleeding. Thrombolytics (eg, tissue-type plasminogen activator [tPA]) cannot be used prophylactically in this high-risk setting because of their short duration of action and risk of causing hemorrhage and central nervous system damage. We found that coupling tPA to carrier red blood cells (RBCs) prolongs and localizes tPA activity within the bloodstream and converts it into a thromboprophylactic agent, RBC/tPA. To evaluate the utility of this new approach for preventing cerebrovascular thrombosis, we examined the effect of RBC/tPA in animal models of cerebrovascular thromboembolism and ischemia. METHODS AND RESULTS: Preformed fibrin microemboli were injected into the middle carotid artery of mice, occluding downstream perfusion and causing severe infarction and 50% mortality within 48 hours. Preinjected RBC/tPA rapidly lysed nascent cerebral thromboemboli, providing rapid, durable reperfusion and reducing morbidity and mortality. These beneficial effects were not achieved by preinjection of tPA, even at a 10-fold higher dose, which increased mortality from 50% to 90% by 10 hours after embolization. RBC/tPA injected 10 minutes after tail amputation to simulate postsurgical hemostasis did not cause bleeding from the wound, whereas soluble tPA caused profuse bleeding. RBC/tPA neither aggravated brain damage caused by focal ischemia in a filament model of middle carotid artery occlusion nor caused postthrombotic hemorrhage in hypertensiverats. CONCLUSIONS: These results suggest a potential RBC/tPA utility as thromboprophylaxis in patients who are at risk for acute cerebrovascular thromboembolism.
Authors: M F Newman; J L Kirchner; B Phillips-Bute; V Gaver; H Grocott; R H Jones; D B Mark; J G Reves; J A Blumenthal Journal: N Engl J Med Date: 2001-02-08 Impact factor: 91.245
Authors: J A Chalela; I Katzan; D S Liebeskind; P Rasmussen; O Zaidat; J I Suarez; D Chiu; R P Klucznick; E Jauch; B L Cucchiara; J Saver; S E Kasner Journal: Stroke Date: 2001-06 Impact factor: 7.914
Authors: Juan-Carlos Murciano; David Harshaw; David G Neschis; Lauren Koniaris; Khalil Bdeir; Sandra Medinilla; Aron B Fisher; Michael A Golden; Douglas B Cines; Marian T Nakada; Vladimir R Muzykantov Journal: Am J Physiol Lung Cell Mol Physiol Date: 2002-03 Impact factor: 5.464
Authors: Zhenggang Zhang; Li Zhang; Manuel Yepes; Quan Jiang; Qingjiang Li; Polly Arniego; Timothy A Coleman; Daniel A Lawrence; Michael Chopp Journal: Circulation Date: 2002-08-06 Impact factor: 29.690
Authors: William M Armstead; Kumkum Ganguly; John Riley; J Willis Kiessling; Douglas B Cines; Abd A R Higazi; Sergei Zaitsev; Vladimir R Muzykantov Journal: Pediatr Crit Care Med Date: 2011-11 Impact factor: 3.624
Authors: Anvay Ukidve; Zongmin Zhao; Alexandra Fehnel; Vinu Krishnan; Daniel C Pan; Yongsheng Gao; Abhirup Mandal; Vladimir Muzykantov; Samir Mitragotri Journal: Proc Natl Acad Sci U S A Date: 2020-07-14 Impact factor: 11.205
Authors: Sergei Zaitsev; Sergei Zaitzev; Dirk Spitzer; Juan-Carlos Murciano; Bi-Sen Ding; Samira Tliba; M Anna Kowalska; Khalil Bdeir; Alice Kuo; Victoria Stepanova; John P Atkinson; Mortimer Poncz; Douglas B Cines; Vladimir R Muzykantov Journal: J Pharmacol Exp Ther Date: 2009-12-01 Impact factor: 4.030
Authors: Juan-Carlos Murciano; Abd Al-Roof Higazi; Douglas B Cines; Vladimir R Muzykantov Journal: J Control Release Date: 2009-07-16 Impact factor: 9.776